Benjamin Hohl

CIK: 0001882764

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)44 (57.1%)

Position reduction

Option Exercises (M)31 (40.3%)

Derivative conversions

Awards (A)2 (2.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ELVN

Enliven Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (77 total)

ELVN
Enliven Therapeutics, Inc.
Oct 19, 2026
Exercise(M)
Direct
6K shares at avg. $14.85$89K
ELVN
Enliven Therapeutics, Inc.
Oct 19, 2026
Sale(S)
Direct
6K shares at avg. $38.48$232K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
3.5K shares at avg. $50.03$177K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Exercise(M)
Direct
4K shares at avg. $14.85$59K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
2.2K shares at avg. $50.72$111K
ELVN
Enliven Therapeutics, Inc.
Sep 17, 2026
Sale(S)
Direct
289 shares at avg. $51.49$15K
ELVN
Enliven Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
4.6K shares at avg. $58.35$270K
ELVN
Enliven Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
1.4K shares at avg. $59.35$82K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
2.6K shares at avg. $53.38$141K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
369 shares at avg. $51.48$19K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
123 shares at avg. $53.87$7K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
2.6K shares at avg. $52.32$134K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Sale(S)
Direct
324 shares at avg. $49.97$16K
ELVN
Enliven Therapeutics, Inc.
Jul 17, 2026
Exercise(M)
Direct
1.1K shares at avg. $2.48$3K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Exercise(M)
Direct
6K shares at avg. $2.48$15K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
1.4K shares at avg. $42.78$59K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
3.4K shares at avg. $43.86$149K
ELVN
Enliven Therapeutics, Inc.
Jun 17, 2026
Sale(S)
Direct
1.2K shares at avg. $44.75$55K
ELVN
Enliven Therapeutics, Inc.
Mar 6, 2026
Sale(S)
Direct
10K shares at avg. $29.58$296K
ELVN
Enliven Therapeutics, Inc.
Feb 12, 2026
Award(A)
Direct
25K shares-
ELVN
Enliven Therapeutics, Inc.
Dec 22, 2025
Exercise(M)
Direct
13K shares at avg. $2.48$32K
ELVN
Enliven Therapeutics, Inc.
Sep 29, 2025
Exercise(M)
Direct
3.3K shares at avg. $2.48$8K
ELVN
Enliven Therapeutics, Inc.
Sep 29, 2025
Sale(S)
Direct
3.3K shares at avg. $20.40$66K
ELVN
Enliven Therapeutics, Inc.
Aug 27, 2025
Sale(S)
Direct
3.3K shares at avg. $20.63$67K
ELVN
Enliven Therapeutics, Inc.
Aug 27, 2025
Exercise(M)
Direct
3.3K shares at avg. $2.48$8K

		Type	Shares	Price		Ownership
Oct 19, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	6,018	$14.85	$89,367	Direct
Oct 19, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	6,018	$38.48	$231,546	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,535	$50.03	$176,851	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	3,982	$14.85	$59,133	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,194	$50.72	$111,270	Direct
Sep 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	289	$51.49	$14,881	Direct
Aug 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	4,630	$58.35	$270,168	Direct
Aug 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,388	$59.35	$82,383	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,638	$53.38	$140,823	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	369	$51.48	$18,997	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	123	$53.87	$6,626	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	2,564	$52.32	$134,143	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	324	$49.97	$16,191	Direct
Jul 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	1,072	$2.48	$2,659	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	6,018	$2.48	$14,925	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,379	$42.78	$59,001	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,401	$43.86	$149,179	Direct
Jun 17, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	1,238	$44.75	$55,397	Direct
Mar 6, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	10,000	$29.58	$295,839	Direct
Feb 12, 2026	ELVN Enliven Therapeutics, Inc.	Award(A)	25,000	-	$0	Direct
Dec 22, 2025	ELVN Enliven Therapeutics, Inc.	Exercise(M)	13,000	$2.48	$32,240	Direct
Sep 29, 2025	ELVN Enliven Therapeutics, Inc.	Exercise(M)	3,250	$2.48	$8,060	Direct
Sep 29, 2025	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,250	$20.40	$66,291	Direct
Aug 27, 2025	ELVN Enliven Therapeutics, Inc.	Sale(S)	3,250	$20.63	$67,039	Direct
Aug 27, 2025	ELVN Enliven Therapeutics, Inc.	Exercise(M)	3,250	$2.48	$8,060	Direct

1-25 of 77 transactions

About Hohl Benjamin

Hohl Benjamin (SEC CIK 0001882764) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc. (ELVN).

Signal8 holds 31 ownership filings by Hohl Benjamin, all Form 4s, filed between Oct 1, 2024 and Oct 21, 2026. Those filings report 77 transactions, from Sep 27, 2024 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hohl Benjamin's filings is in BURLINGAME, CA.

Recent filings by Hohl Benjamin

Oct 19, 2026: Option exercise of ELVN shares (Form 4, code M).
Oct 19, 2026: Open-market sale of ELVN shares (Form 4, code S).
Sep 17, 2026: Open-market sale of ELVN shares (Form 4, code S).
Sep 17, 2026: Option exercise of ELVN shares (Form 4, code M).
Sep 17, 2026: Open-market sales of ELVN shares (2 lines, Form 4, code S).

Other insiders filing for Enliven Therapeutics, Inc. (ELVN)

Kunkel Lori Anne, Officer
Collins Helen Louise, CHIEF MEDICAL OFFICER
BALL KRISTINE M, Director
Garland J. Scott, Director
Derynck Mika K, Director
ORBIMED ADVISORS LLC, 10% Owner

How to read Form 4 transaction codes